Evidence map›Paper›PMID 38230908›Full record

ReviewCancer medicine2024

Unveiling the potential anti-cancer activity of calycosin against multivarious cancers with molecular insights: A promising frontier in cancer research.

Md Sohel, Fatema Tuj Zahra Shova, Shahporan Shuvo, Taiyara Mahjabin, Md Mojnu Mia, Dibyendu Halder, Hafizul Islam, Md Roman Mogal, Partha Biswas, Hasi Rani Saha and 2 more

Open access · goldAbstract readReview
In one paragraph

Review in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Biomolecules · 2024
    Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Md SohelBiochemistry and Molecular Biology, Primeasia University, Dhaka, Bangladesh.ORCID 0000-0001-8344-1976
Fatema Tuj Zahra ShovaBiotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Tangail, Bangladesh.
Shahporan ShuvoBiochemistry and Molecular Biology, Mawlana Bhashani Science and Technology University, Tangail, Bangladesh.
Taiyara MahjabinBiochemistry and Molecular Biology, Mawlana Bhashani Science and Technology University, Tangail, Bangladesh.
Md Mojnu MiaBiotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Tangail, Bangladesh.
Dibyendu HalderBiochemistry and Molecular Biology, Mawlana Bhashani Science and Technology University, Tangail, Bangladesh.
Hafizul IslamBiochemistry and Molecular Biology, Mawlana Bhashani Science and Technology University, Tangail, Bangladesh.
Md Roman MogalBiochemistry and Molecular Biology, Mawlana Bhashani Science and Technology University, Tangail, Bangladesh.
Partha BiswasDepartment of Genetic Engineering and Biotechnology, Faculty of Biological Science and Technology, Jashore University of Science and Technology (JUST), Jashore, Bangladesh.
Hasi Rani SahaBiochemistry and Molecular Biology, Primeasia University, Dhaka, Bangladesh.
Bidhan Chandra SarkarBiochemistry and Molecular Biology, Primeasia University, Dhaka, Bangladesh.
Abdullah Al MamunBiochemistry and Molecular Biology, Mawlana Bhashani Science and Technology University, Tangail, Bangladesh.ORCID 0000-0003-3839-9603
Mawlana Bhashani Science and Technology University · BDPrimeasia University · BD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCalycosin may be a potential candidate regarding chemotherapeutic agent, because already some studies against multivarious cancer have been made with this natural compound.

aimThis review elucidated a brief overview of previous studies on calycosin potential effects on various cancers and its potential mechanism of action. METHODOLOGY: Data retrieved by systematic searches of Google Scholar, PubMed, Science Direct, Web of Science, and Scopus by using keywords including calycosin, cancer types, anti-cancer mechanism, synergistic, and pharmacokinetic and commonly used tools are BioRender, ChemDraw Professional 16.0, and ADMETlab 2.0.

resultsBased on our review, calycosin is available in nature and effective against around 15 different types of cancer. Generally, the anti-cancer mechanism of this compound is mediated through a variety of processes, including regulation of apoptotic pathways, cell cycle, angiogenesis and metastasis, oncogenes, enzymatic pathways, and signal transduction process. These study conducted in various study models, including in silico, in vitro, preclinical and clinical models. The molecular framework behind the anti-cancer effect is targeting some oncogenic and therapeutic proteins and multiple signaling cascades. Therapies based on nano-formulated calycosin may make excellent nanocarriers for the delivery of this compound to targeted tissue as well as particular organ. This natural compound becomes very effective when combined with other natural compounds and some standard drugs. Moreover, proper use of this compound can reverse resistance to existing anti-cancer drugs through a variety of strategies. Calycosin showed better pharmacokinetic properties with less toxicity in human bodies.

conclusionCalycosin exhibits excellent potential as a therapeutic drug against several cancer types and should be consumed until standard chemotherapeutics are available in pharma markets.

Indexed as

IsoflavonesNeoplasmsHumansOncogenesResearch7,3'-dihydroxy-4'-methoxyisoflavoneIsoflavonesanti-cancer perspectivecalycosinmolecular pharmacologynanoformulationpharmacokineticssynergistic

Identifiers

PMID38230908
PMCPMC10905684
OpenAlexW4390944736

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.